论文部分内容阅读
甲状腺癌占全身恶性肿瘤的1%,对于分化型甲状腺癌,目前国内外公认治疗方案是“手术切除加~(131)I治疗加促甲状腺激素(thyroid stimulating hormone,TSH)抑制治疗”的联合方案~([1])。但~(131)I除了可以被甲状腺吸收之外,也可以被其他组织吸收,造成一系列不良反应。131I治疗相关唾液腺炎是较常见的放射性碘治疗后并发症,其症状有唾液腺疼痛、肿胀及口干等,影响患者的生活质量。因此,对
Thyroid cancer accounts for 1% of systemic malignancies. For differentiated thyroid cancer, the accepted treatment program at home and abroad is “surgical resection plus 131I treatment plus thyroid stimulating hormone (TSH) inhibition therapy” Joint program ~ ([1]). But ~ (131) I in addition to being absorbed by the thyroid, but also can be absorbed by other tissues, causing a series of adverse reactions. 131I treatment-related salivary gland inflammation is a more common complication of radioactive iodine treatment, the symptoms of salivary gland pain, swelling and dry mouth, affecting the quality of life of patients. So yes